World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0020154738
Reproduction Date:

Title: Carmofur  
Author: World Heritage Encyclopedia
Language: English
Subject: Chemotherapy, Cell-cycle nonspecific antineoplastic agents, Hazardous drugs, Thiopurine, Pyrimidine analogue
Collection: Organofluorides, Pyrimidine Antagonists, Pyrimidinediones
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
Routes Oral
CAS number  YesY
ATC code L01
ChemSpider  N
Synonyms 1-hexylcarbamoyl-5-fluorouracil
Chemical data
Formula C11H16FN3O3 
Mol. mass 257.261 g/mol

Carmofur (INN) or HCFU (1-hexylcarbamoyl-5-fluorouracil) is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil.


  • Mechanism of action 1
  • Uses 2
    • Breast Cancer 2.1
    • Colorectal Cancer 2.2
  • Adverse effects 3
  • References 4

Mechanism of action


Breast Cancer

Colorectal Cancer

Carmofur, in its oral form, has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients. Trials and meta-analyses have confirmed that the drug is effective on patients with this cancer type, extending their survival.[1]

Adverse effects

As fluorouracil, carmofur has been known to induce leukoencephalopathy.[2][3][4]


  1. ^ Sakamoto, J; Hamada, C; Rahman, M; Kodaira, S; Ito, K; Nakazato, H; Ohashi, Y; Yasutomi, M (2005). "An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer". Japanese Journal of Clinical Oncology 35 (9): 536–544.  
  2. ^ Yamada T, Okamura S, Okazaki T, et al. (June 1989). "Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature". Asia Oceania J Obstet Gynaecol 15 (2): 161–8.  
  3. ^ Mizutani T (February 2008). "[Leukoencephalopathy caused by antineoplastic drugs]". Brain Nerve (in Japanese) 60 (2): 137–41.  
  4. ^ Baehring JM, Fulbright RK (May 2008). "Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients". J Neurol Neurosurg Psychiatr 79 (5): 535–9.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.